United Therapeutics Corp/ US91307C1027 /
10/09/2024 21:59:50 | Chg. -6.05 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
342.39USD | -1.74% | 14,821 Turnover: 5.09 mill. |
-Bid Size: - | -Ask Size: - | 15.24 bill.USD | - | 16.28 |
Assets
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Property and Equipment | 495.7740 | 489.3000 | 545.7000 | 699.7000 | 738.5000 | ||||||
Intangible Assets | - | - | - | - | - | ||||||
Long-Term Investments | 38.0020 | 2.3000 | 502.7000 | 442.6000 | 767.5000 | ||||||
Fixed Assets | - | - | 1,431.5000 | 1,633 | 2,048.9000 | ||||||
Inventories | 81.3340 | 100 | 107.9000 | 101 | 93.4000 | ||||||
Accounts Receivable | 192.8270 | 214.5000 | 297.1000 | 175.7000 | 151.4000 | ||||||
Cash and Cash Equivalents | 831.7980 | 1,023 | 705.1000 | 669.2000 | 738.4000 | ||||||
Current Assets | 1,275.3350 | 1,424.8000 | 1,447.9000 | 1,768 | 1,864.5000 | ||||||
Total Assets | 2,184.4450 | 2,325.6000 | 2,879.4000 | 3,401 | 3,913.4000 |
Liabilities
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Accounts Payable | - | - | - | - | - | ||||||
Long-term debt | - | - | 250 | 250 | 600 | ||||||
Liabilities to Banks | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 600 | ||||||
Provisions | - | - | - | - | - | ||||||
Liabilities | 595.8930 | 474.3000 | 777.6000 | 612.4000 | 1,133 | ||||||
Share Capital | .6900 | .7000 | .7000 | .7000 | .7000 | ||||||
Total Equity | 1,588.5520 | 1,851.3000 | 2,101.8000 | 2,788.6000 | 2,780.4000 | ||||||
Minority Interests | - | - | - | - | - | ||||||
Total liabilities equity | 2,184.4450 | 2,325.6000 | 2,879.4000 | 3,401 | 3,913.4000 |
Income Statement
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 1,465.7610 | 1,598.8000 | 1,725.3000 | 1,627.8000 | 1,448.8000 | ||||||
Depreciation (total) | 32.9210 | - | - | - | - | ||||||
Operating Result | 699.0150 | 1,061.7000 | 814.9000 | 805.4000 | -187.6000 | ||||||
Interest Income | -4.7350 | -3.9000 | -9 | 14.7000 | 0.0000 | ||||||
Income Before Taxes | 1,044.4370 | 1,060.2000 | 769.5000 | 758.9000 | -165 | ||||||
Income Taxes | -392.7980 | -346.5000 | -351.6000 | -169.7000 | 60.5000 | ||||||
Minority Interests Profit | - | - | - | - | - | ||||||
Net Income | 651.6390 | 713.7000 | 417.9000 | 589.2000 | -104.5000 |
Per Share
Cash Flow
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flow from Operating Activities | 382.7610 | 643.6000 | 474.2000 | 778.4000 | -206.6000 | ||||||
Cash Flow from Investing Activities | 503.5790 | 48.3000 | -835.6000 | -820.6000 | -335.4000 | ||||||
Cash Flow from Financing | -446.9430 | -497.7000 | 43.3000 | 6.3000 | 611.2000 | ||||||
Decrease / Increase in Cash | 434.1010 | 191.2000 | -317.9000 | -35.9000 | 69.2000 | ||||||
Employees | 750 | 750 | 800 | 860 | 920 |